Grannum Sant - Photocure Director
| PHO Stock | NOK 54.40 0.50 0.93% |
Director
Dr. Grannum R. Sant was Director of Photocure ASA since April 28, 2016. Grannum R. Sant is currently an independent consultant for medical organizations and biopharmaceutical industry, and Professor of Urology at Tufts University School of Medicine in Boston, USA. Dr. Sant has a broad and deep international experience in pharma and academia. From 2003 to 2013 he held senior leadership roles including Vice President and Head of Medical Affairs for urology and oncology at Sanofi US. His last pharma position was as Vice President, Head of Global Medical Affairs Rare Genetic Diseases at Genzyme. Dr. Sant is a board certified urologist in the US and prior to 2003 was Professor and Chair of the Urology at Tufts University School of Medicine. since 2016.
| Tenure | 8 years |
| Phone | (47) 22 06 22 18 |
| Web | www.photocure.no |
Photocure Management Efficiency
The company has return on total asset (ROA) of (0.0309) % which means that it has lost $0.0309 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1567) %, meaning that it generated substantial loss on money invested by shareholders. Photocure's management efficiency ratios could be used to measure how well Photocure manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Brita Eilertsen | Next Biometrics Group | N/A | |
| Line Lunde | Lumi Gruppen AS | N/A | |
| Jogeir Romestrand | Havila Shipping ASA | 56 | |
| SvennTore Larsen | Next Biometrics Group | 57 | |
| Kjartan Medle | Havila Shipping ASA | 40 | |
| Robert Mueller | Next Biometrics Group | N/A | |
| Roger Granheim | Havila Shipping ASA | 50 | |
| Michael Brekke | Lumi Gruppen AS | N/A | |
| Ketil Fridheim | Next Biometrics Group | N/A | |
| Emine Lundkvist | Next Biometrics Group | N/A | |
| Janicke Driveklepp | Havila Shipping ASA | 47 | |
| Nina Skage | Havila Shipping ASA | 53 | |
| Hege Rabben | Havila Shipping ASA | 44 | |
| Ralph Hoibakk | Next Biometrics Group | N/A | |
| Inger Orstavik | Next Biometrics Group | N/A | |
| Ngoc Dinh | Next Biometrics Group | N/A | |
| Marit Instanes | Next Biometrics Group | N/A | |
| Emanuel Lang | Next Biometrics Group | N/A | |
| Helge Aarseth | Havila Shipping ASA | 68 | |
| Petter Fjellstad | Next Biometrics Group | N/A | |
Management Performance
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0309 |
Photocure Leadership Team
Elected by the shareholders, the Photocure's board of directors comprises two types of representatives: Photocure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Photocure. The board's role is to monitor Photocure's management team and ensure that shareholders' interests are well served. Photocure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Photocure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathleen Deardorff, COO | ||
| Jan Egberts, Chairman of the Board | ||
| Tolv Hillestad, Group Controller | ||
| Einar Antonsen, Director | ||
| Patricia Kelly, VP HR | ||
| Jeremy Bahr, Chief Business Officer | ||
| David Moskowitz, Head Relations | ||
| Grete Hogstad, Vice President of Strategic Marketing | ||
| Tove Ringvold, Director | ||
| Anders Neijber, Clinical Affairs | ||
| Geoffrey Coy, VP Operations | ||
| Synne Roine, Director | ||
| Erik Dahl, Chief Officer | ||
| Xavier Yon, Director | ||
| Johanna Holldack, Director | ||
| Kari MD, Head Devel | ||
| Gwen Mellincoff, Director | ||
| Ambaw Bellete, Head of United States Cancer Commercial Operations | ||
| Espen Njastein, Head of Nordic Cancer Commercial Operations | ||
| BenteLill Romoren, Chairman of the Board | ||
| Lars Ronn, Director | ||
| Kjetil Hestdal, President CEO | ||
| Gry Stensrud, VP of Technical Devel. and Operations | ||
| Daniel Schneider, President CEO | ||
| Grannum Sant, Director | ||
| Inger Heglund, Vice President of Research and Development | ||
| Tom Pike, Director |
Photocure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Photocure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0309 | |||
| Profit Margin | (0.20) % | |||
| Operating Margin | (0.1) % | |||
| Current Valuation | 2.77 B | |||
| Shares Outstanding | 27.11 M | |||
| Shares Owned By Insiders | 2.98 % | |||
| Shares Owned By Institutions | 48.69 % | |||
| Price To Earning | 91.78 X | |||
| Price To Book | 6.33 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Photocure using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Photocure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Photocure Stock analysis
When running Photocure's price analysis, check to measure Photocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Photocure is operating at the current time. Most of Photocure's value examination focuses on studying past and present price action to predict the probability of Photocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Photocure's price. Additionally, you may evaluate how the addition of Photocure to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |